Cytek Biosciences (CTKB) Invested Capital (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Invested Capital data on file, last reported at $328.0 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 13.8% year-over-year to $328.0 million; the trailing twelve-month figure through Mar 2026 stood at $328.0 million (down 13.8% YoY), and the FY2025 full-year result was $342.3 million, down 13.74% from the prior year.
• Invested Capital for Q1 2026 stood at $328.0 million, down from $342.3 million in the prior quarter.
• Across five years, Invested Capital topped out at $427.8 million in Q4 2022 and bottomed at $328.0 million in Q1 2026.
• The 5-year median for Invested Capital is $394.7 million (2023), against an average of $394.3 million.
• The widest annual swing landed in 2022, when Invested Capital jumped 36940.18%; it then slipped 13.8% in 2026.
• A 5-year view of Invested Capital shows it stood at $427.8 million in 2022, then slipped by 7.74% to $394.7 million in 2023, then advanced by 0.53% to $396.8 million in 2024, then retreated by 13.74% to $342.3 million in 2025, then slipped by 4.16% to $328.0 million in 2026.
• The last three Invested Capital figures came in at $328.0 million (Q1 2026), $342.3 million (Q4 2025), and $379.2 million (Q3 2025), per Business Quant data.

Peer Comparison